IRVINE, Calif., September 5, 2018 (Newswire.com) - The 2019 Sternfels Prize for Drug Safety Discoveries application window opened today, according to contest officials. The Sternfels Prize recognizes research to reduce the risk associated with the real-world use of pharmaceuticals.
The Prize was created to incentivize pharmacologists, pharmacists, medical practitioners, academics and students to think about ways to prevent the side effects patients face due to polypharmacy, interacting co-morbidities and genetics. The Prize was named in honor of Edith and Ernst Sternfels. Ernst was an engineer involved in the design and construction of chemical plants around the world, including many involved in the synthesis of life-improving molecules. Edith was a nurse, dedicated to the welfare and treatment of patients. Together, they represent the breadth of modern medicine, from highly technical science to personal attention and care.
The $35,000 Sternfels Prize is awarded annually to the most novel, clinically relevant and testable idea to reduce life-threatening drug-drug, drug-disease or pharmacogenomic interactions.
Judges of the prestigious 2019 prize include Dr. David Greenblatt of Tufts University, Dr. Lawrence Lesko from the University of Florida and Dr. Dan Roden at Vanderbilt University School of Medicine.
“We seek to recognize the most outstanding research in the field of pharmaceutical safety and look forward to reviewing the outstanding work of this year’s applicants,” Dr. Roden said.
Sundar Srinivasan, chief executive officer of Emerald Lake Safety (ELS), which is the 2019 underwriter of the award, said, “We’re extremely pleased to be associated with the Sternfels Prize again this year because our company shares the same desire to eliminate the serious adverse events patients suffer from when taking medications.” For more information about ELS, visit www.emeraldlakesafety.com.
Now in its third year, past Sternfels winners include Merrie Mosedale for HLA-intermediated drug-induced liver injury analyses and Jennifer Le for methods of improving vancomycin dosing in conjunction with extracorporeal life support.
In addition to the cash prize, the overall winner will also receive substantial assistance in securing funding for further research. And this year for the first time, the top 30 entries will receive a free Apple® iPad for their efforts. Responses submitted before Dec. 15, 2018, will receive critical feedback ahead of the closing deadline, Jan. 31, 2019.
All submissions are held in confidence and remain the property of the applicant and/or their research institution. For more information, visit www.sternfelsprize.org.
Source: The Sternfels Prize for Drug Safety Discoveries